

(51) International Patent Classification:
C07D 471/04 (2006.01)(21) International Application Number:
PCT/US2013/078398(22) International Filing Date:
31 December 2013 (31.12.2013)

(25) Filing Language: English



(26) Publication Language: English

(30) Priority Data:
61/751,993 14 January 2013 (14.01.2013) US(71) Applicant: E. I. DU PONT DE NEMOURS AND COM-
PANY [US/US]; 1007 Market Street, Wilmington,
Delaware 19898 (US).(72) Inventor: EL-AWA, Ahmad; 1409 Stoneleigh Road,
Wilmington, Delaware 19803 (US).(74) Agent: LETT, Renee, M.; E. I. du Pont de Nemours and
Company, Legal Patent Records Center, Chestnut Run
Plaza 721/2340, 974 Centre Road, PO Box 2915 Wilming-
ton, Delaware 19805 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PREPARATION OF NEMATOCIDAL SULFONAMIDES

(57) Abstract: Disclosed is a method for preparing a compound of Formula 1 by coupling of intermediates of Formula 2 and For-
mula 3 in the presence of an aluminum reagent of Formula 4 [Formula should be inserted here] wherein R¹, R^{2a}, R^{2b} and R^{2c} are
defined in the disclosure.

TITLE

PREPARATION OF NEMATOCIDAL SULFONAMIDES

This invention relates to a novel method for preparing 8-chloro-*N*-[(2-chloro-5-methoxyphenyl)sulfonyl]-6-(trifluoromethyl)-imidazo[1,2-*a*]pyridine-2-carboxamide.

5


BACKGROUND OF THE INVENTION

Preparation of 8-chloro-*N*-[(2-chloro-5-methoxyphenyl)sulfonyl]-6-(trifluoromethyl)-imidazo[1,2-*a*]pyridine-2-carboxamide and its use as a nematocide is described in PCT Patent Publication WO 2010/129500. However, the need continues for new or improved methods suitable for rapidly and economically providing 8-chloro-*N*-[(2-chloro-5-methoxyphenyl)sulfonyl]-6-(trifluoromethyl)-imidazo[1,2-*a*]pyridine-2-carboxamide.


10

SUMMARY OF THE INVENTION

The present invention provides a method for preparing a compound of Formula 1



comprising (A) contacting a compound of Formula 2




15


wherein

R¹ is C₁-C₄ alkyl

with a compound of Formula 3



and at least one aluminum reagent of Formula 4



4

wherein

R^{2a} , R^{2b} and R^{2c} are each independently H, Cl or C_1 - C_4 alkyl

in the presence of an inert solvent to form a first reaction product,

5 (B) contacting the first reaction product with an C_1 - C_4 alkanol to form a second reaction product

and (C) contacting the second reaction product with water and a protic acid to give the compound of Formula 1.

BRIEF DESCRIPTION OF THE DRAWINGS

10 FIGURE 1 shows Cu($\text{K}\alpha 1$)-powder X-ray diffraction patterns of polymorph Forms TS, XS and A of Compound 1 showing absolute X-ray intensity in counts graphed against 2θ reflection positions in degrees.

DETAILS OF THE INVENTION

As used herein, the terms “comprises,” “comprising,” “includes,” “including,” “has,”
15 “having,” “contains,” “containing,” “characterized by” or any other variation thereof, are intended to cover a non-exclusive inclusion, subject to any limitation explicitly indicated. For example, a composition, mixture, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process, method,
20 article, or apparatus.

The transitional phrase “consisting of” excludes any element, step, or ingredient not specified. If in the claim, such phrase would close the claim to the inclusion of materials other than those recited except for impurities ordinarily associated therewith. When the phrase “consisting of” appears in a clause of the body of a claim, rather than immediately
25 following the preamble, it limits only the element set forth in that clause; other elements are not excluded from the claim as a whole.

Where applicants have defined an invention or a portion thereof with an open-ended term such as “comprising,” it should be readily understood that (unless otherwise stated) the description should be interpreted to also describe such an invention using the terms
30 “consisting essentially of” or “consisting of.”

Further, unless expressly stated to the contrary, “or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).

Also, the indefinite articles “a” and “an” preceding an element or component of the invention are intended to be nonrestrictive regarding the number of instances (i.e. occurrences) of the element or component. Therefore “a” or “an” should be read to include one or at least one, and the singular word form of the element or component also includes the plural unless the number is obviously meant to be singular.


The term “ambient temperature” or “room temperature” as used in this disclosure refers to a temperature between about 18 °C and about 28 °C.

The term “polymorph” refers to a particular crystal form (i.e. structure of crystal lattice) of a chemical compound that can exist in more than one crystal form in the solid state.


In the above recitations, the term “alkyl”, includes straight-chain or branched alkyl, such as, methyl, ethyl, *n*-propyl, *i*-propyl, or the different butyl isomers. Haloalkanes are alkanes partially or fully substituted with halogen atoms (fluorine, chlorine, bromine or iodine). Examples of haloalkanes include CH₂Cl₂, ClCH₂CH₂Cl and CCl₃CH₃. Halogenated benzenes are benzenes partially or fully substituted with halogen atoms (fluorine, chlorine, bromine or iodine). Examples of halogenated benzenes include Chlorobenzene, 1,2-dichlorobenzene and bromo-benzene. C₇-C₁₀ aromatic hydrocarbons are compounds containing one benzene ring which is substituted with alkyl groups. Examples of C₇-C₁₀ aromatic hydrocarbons are toluene, xylenes, ethyl benzene and cumene (*iso*-propylbenzene).

Embodiments of the present invention include:

Embodiment P. A method for preparing the compound of Formula 1



comprising (A) contacting a compound of Formula 2




4


wherein

R^1 is C_1 - C_4 alkyl

with a compound of Formula **3**

**3**

and at least one aluminum reagent of Formula **4p**

**4p**

wherein


each R^2 is independently H, Cl, CH_3 , CH_2CH_3 , or $CH_2CH(CH_3)_2$

in the presence of an inert solvent to form a first reaction product,


(B) contacting the first reaction product with an C_1 - C_4 alkanol to form a second reaction product

and (C) contacting the second reaction product with water and a protic acid to give the compound of Formula **1**.

Embodiment 1. The method of Embodiment P or the method described in the Summary of the Invention for preparing the compound of Formula **1**

**1**

comprising (A) contacting a compound of Formula **2**


**2**

5

wherein

R^1 is C_1 - C_4 alkyl

with a compound of Formula 3



3

and at least one aluminum reagent of Formula 4



4

wherein

R^{2a} , R^{2b} and R^{2c} are each independently H, Cl or C_1 - C_4 alkyl

in the presence of an inert solvent to form a first reaction product,

(B) contacting the first reaction product with an C_1 - C_4 alkanol to form a second reaction product

and (C) contacting the second reaction product with water and a protic acid to give the compound of Formula 1.

Embodiment 2. The method of Embodiment 1 wherein R^1 is CH_3 , CH_2CH_3 , $CH_2CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH_2CH_2CH_3$, $CH_2CH(CH_3)_2$ or $CH_2(CH_3)CH_2CH_3$.

Embodiment 3. The method of Embodiment 2 wherein R^1 is CH_3 or CH_2CH_3 .

Embodiment 4. The method of Embodiment 3 wherein R^1 is CH_2CH_3 .

Embodiment 5. The method of any one of Embodiments 1 through 4 wherein R^{2a} , R^{2b} and R^{2c} are each independently H, Cl, CH_3 , CH_2CH_3 or $CH_2CH(CH_3)_2$.

Embodiment 5p. The method of any one of Embodiments 1 through 4 wherein each R^2 is independently Cl, CH_3 or CH_2CH_3 .

Embodiment 6. The method of Embodiment 5p wherein each R^2 is independently Cl or CH_2CH_3 .

Embodiment 7. The method of any one of Embodiments 1 through 6 wherein the at least one aluminum reagent of Formula 4 comprises one or more compounds selected from the group consisting of $ClAl(CH_2CH_3)_2$, $Cl_2Al(CH_2CH_3)$, $Al(CH_2CH_3)_3$, $Al(CH_3)_3$, $Al[CH_2CH(CH_3)_2]_3$ and $HA[CH_2CH(CH_3)_2]_2$.

Embodiment 8. The method of Embodiment 7 wherein the at least one aluminum reagent of Formula 4 comprises one or more compounds selected from the group consisting of $ClAl(CH_2CH_3)_2$, $Cl_2Al(CH_2CH_3)$ and $Al(CH_2CH_3)_3$.

Embodiment 9. The method of Embodiment 8 wherein the at least one aluminum reagent of Formula 4 comprises $\text{ClAl}(\text{CH}_2\text{CH}_3)_2$.

Embodiment 10. The method of any one of Embodiments 1 through 9 wherein the inert solvent comprises one or more solvents selected from the group consisting of C_1 - C_6 haloalkanes, halogenated benzenes and C_7 - C_{10} aromatic hydrocarbons.

Embodiment 11. The method of Embodiment 10 wherein the inert solvent comprises one or more solvents selected from the group consisting of toluene, xylenes, ethylbenzene, cumene, 1,2-dichloroethane, dichloromethane, 1,1,1-trichloroethane, chlorobenzene, 1,2-dichlorobenzene and *n*-chlorobutane.

Embodiment 12. The method of Embodiment 11 wherein the inert solvent comprises toluene.

Embodiment 12a. The method of Embodiment 11 wherein the inert solvent comprises *n*-chlorobutane.

Embodiment 12b. The method of Embodiment 11 wherein the inert solvent comprises one or more solvents selected from the group consisting of 1,2-dichloroethane, dichloromethane and *n*-chlorobutane.

Embodiment 12c. The method of Embodiment 12b wherein the inert solvent comprises one or more solvents selected from the group consisting of 1,2-dichloroethane and dichloromethane.

Embodiment 12d. The method of Embodiment 12c wherein the inert solvent comprises 1,2-dichloroethane.

Embodiment 12e. The method of Embodiment 12c wherein the inert solvent comprises dichloromethane.

Embodiment 13. The method of any one of Embodiments 1 through 12e wherein in step (A) the temperature is in the range of 20 to 150 °C.

Embodiment 14. The method of Embodiment 13 wherein in step (A) the temperature is in the range of 50 to 100 °C.

Embodiment 15. The method of Embodiment 14 wherein in step (A) the temperature is in the range of 60 to 80 °C.

Embodiment 16. The method of any one of Embodiments 1 through 15 wherein in step (A) the temperature is in the range of 50 to 100 °C, the inert solvent comprises dichloromethane, and the pressure above the inert solvent is in the range of 100 to 700 kPa.

Embodiment 16a. The method of any one of Embodiments 1 through 16 wherein in step (A), the compound of Formula 2 and the compound of Formula 3 are combined in the presence of an inert solvent and then the aluminum reagent of Formula 4 is added.

Embodiment 17. The method of any one of Embodiments 1 through 16a wherein the molar ratio of the compound of Formula 2 to the compound of Formula 3 is in the range of 1.1:1.0 to 1.0:1.1.

Embodiment 18. The method Embodiment 17 wherein the molar ratio of the compound of Formula 2 to the compound of Formula 3 is 1.0:1.0.

Embodiment 19. The method of any one of Embodiments 1 through 18 wherein the molar ratio of the compound of Formula 2 to the aluminum reagent is in the range of 1.0:1.0 to 1.0:1.5.

Embodiment 20. The method of Embodiment 19 wherein the molar ratio of the compound of Formula 2 to the aluminum reagent is 1.0:1.1.

Embodiment 21. The method of any one of Embodiments 1 through 20 wherein in step (B) the C₁-C₄ alkanol comprises one or more alkanols selected from the group consisting of methanol, ethanol, *n*-propanol, *iso*-propanol, *n*-butanol, *iso*-butanol and *sec*-butanol.

Embodiment 22. The method of Embodiment 21 wherein in step (B) the C₁-C₄ alkanol comprises one or more alkanols selected from the group consisting of methanol, ethanol, *n*-propanol or *iso*-propanol.

Embodiment 23. The method of Embodiment 22 wherein in step (B) the C₁-C₄ alkanol comprises *iso*-propanol.

Embodiment 24. The method of any one of Embodiments 1 through 23 wherein in step (B) the molar ratio of the C₁-C₄ alkanol to the compound of Formula 2 is in the range of 2.5:1.0 to 1.8:1.0.

Embodiment 25. The method of Embodiment 24 wherein in step (B) the molar ratio of the C₁-C₄ alkanol to the compound of Formula 2 is 2.0:1.0.

Embodiment 26. The method of any one of Embodiments 1 through 25 wherein in step (B) the temperature is in the range of 20 to 80 °C.

Embodiment 27. The method of Embodiment 26 wherein in step (B) the temperature is in the range of 50 to 80 °C.

Embodiment 28. The method of any one of Embodiments 1 through 27 wherein in step (C) the protic acid comprises one or more protic acids selected from the group consisting of acetic acid, hydrochloric acid, citric acid, formic acid and sulfuric acid.

Embodiment 29. The method of Embodiment 28 wherein in step (C) the protic acid comprises acetic acid.

Embodiment 30. The method of any one of Embodiments 1 through 29 wherein in step (C) the temperature is in the range of 20 to 30 °C.

Embodiment 31. The method of any one of Embodiments 1 through 30 wherein in step (C) the molar ratio of the protic acid to the compound of Formula **2** is in the range of 3.0:1.0 to 2.0:1.0.


Embodiment 32. The method of Embodiment 31 wherein in step (C) the molar ratio of the protic acid to the compound of Formula **2** is 2.5:1.0.

Embodiments of this invention, including Embodiments P and 1–32 above as well as any other embodiments described herein, can be combined in any manner, and the descriptions of variables in the embodiments pertain not only to the aforescribed method for preparing the compound of Formula **1**, but also to the starting compounds and intermediate compounds useful for preparing the compound of Formula **1** by this method. In the Embodiments of this invention, references to Formula **4** are considered to also refer to Formula **4p**.

In the following Scheme 1 the definition of R^1 and R^2 in the compounds of Formulae **2** and **4** are as defined above in the Summary of the Invention and description of Embodiments unless otherwise indicated.

In the method of the invention, a compound of Formula **2** is reacted with a compound of Formula **3** in the presence of an aluminum reagent of Formula **4** to form the compound of Formula **1** after treatment with an alcohol and aqueous acid. Step (A) of the method of the invention involves coupling of a compound of Formula **2** with a compound of Formula **3** in the presence of at least one aluminum reagent of Formula **4** to form a first reaction product. In step (B), the first reaction product, i.e. PA , is treated with an C_1 - C_4 alkanol to form a second reaction product. In step (C), the second reaction product, i.e. PB , is treated with a protic acid in water to give the compound of Formula **1** as shown in Scheme 1.

Scheme 1



The first reaction product **PA** and the second reaction product **PB** are usually not isolated but believed to be aluminum complexes. The reaction mixture containing **PA** is used directly in Step (B) and the reaction mixture containing **PB** is used directly in Step (C).

Examples of aluminum reagents of Compound **4** which can be used in step (A) of the coupling of compounds of Formula **2** with compounds of Formula **3** include but are not limited to ClAl(CH₂CH₃)₂, Cl₂Al(CH₂CH₃), Al(CH₂CH₃)₃, Al(CH₃)₃, Al[CH₂CH(CH₃)₂]₃ and HAl[CH₂CH(CH₃)₂]₂. A particularly useful aluminum reagent for the coupling of Step (A) is ClAl(CH₂CH₃)₂, i.e. diethylaluminum chloride.

Aluminum reagents are sensitive to the presence of both air and water in the process of Scheme 1. Many, such as diethylaluminum chloride, are pyrophoric, and spontaneously ignite in the presence of air and water. Therefore the process is preferentially carried out in a substantially oxygen and water free solvent. Standard techniques can be used to obtain oxygen-free solvents including, for example, refluxing or distilling the solvents in an inert atmosphere such as nitrogen or argon, or sparging the solvents with an inert gas such as nitrogen or argon. Standard drying agents such as molecular sieves, potassium carbonate and magnesium sulfate may be used.

The coupling of compounds of Formula **2** with compounds of Formula **3** in step (A) can be accomplished in inert solvents such as C₁-C₆ haloalkanes, halogenated benzenes and C₇-C₁₀ aromatic hydrocarbons. Examples of these types of solvents include but are not limited to toluene, xylenes, ethylbenzene, cumene, 1,2-dichloroethane, dichloromethane, 1,1,1-trichloroethane, chlorobenzene, 1,2-dichlorobenzene and *n*-chlorobutane. Particularly

useful solvents for this coupling are toluene, *n*-chlorobutane, 1,2-dichloroethane and dichloromethane. Haloalkane solvents (e.g. *n*-chlorobutane, 1,2-dichloroethane and dichloromethane) are especially useful because the Compound of Formula 1 can be isolated in unsolvated form (polymorph Form A) from them.

5 The coupling of compounds of Formula 2 with compounds of Formula 3 in step (A) can be run under a broad range of temperatures, i.e. temperatures in the range of 20 to 150 °C. Temperatures in the range of 50 to 100 °C are particularly useful. Temperatures in the range of 60 to 80 °C are especially useful.

10 The reaction in dichloromethane (boiling point 40 °C) at atmospheric pressure, takes about 24 hours to reach completion. In order to reduce the reaction time in dichloromethane, the reaction can be run at reaction temperatures (50 to 100 °C) above the boiling point under a moderate pressure of 100 to 700 kPa (about 15 to 100 psi). Reaction times at the higher temperatures are much shorter (1 to 3 hours). Standard engineering techniques and equipment known in the art of process chemistry can be used to maintain a reaction vessel
15 under temperatures and pressures in this range.

In step (A) the molar ratio of the compound of Formula 2 to the compound of Formula 3 is in the range of 1.1:1.0 to 1.0:1.1. An especially useful molar ratio of the compound of Formula 2 to the compound of Formula 3 is 1.0:1.0.

20 In step (A) the molar ratio of the compound of Formula 2 to the aluminum reagent of Formula 4 is in the range of 1.0:1.0 to 1.0:1.5. An especially useful molar ratio of the compound of Formula 2 to the compound of Formula 3 is 1.0:1.1.

25 Step (A) of Scheme 1 can be carried out using standard engineering practice. Preferably the reagents are charged to the reaction vessel in an oxygen-free environment. Standard techniques for obtaining an oxygen-free environment can be used, including, for example, evacuating the reaction vessel and re-pressurizing to atmospheric pressure with an inert gas. This method can be repeated two or more times to further reduce the oxygen present in the reaction vessel.

30 The reagents of Formulae 2, 3 and 4 in step (A) of the invention can be combined in a variety of orders. A particularly useful method is to combine the compound of Formula 2 and the compound of Formula 3 in the presence of an inert solvent followed by addition of the aluminum reagent of Formula 4. The rate of addition of the aluminum reagent should be slow enough to maintain the temperature in the range of 60 to 80 °C. After the addition of the aluminum reagent 4 the reaction mixture is typically a thick slurry requiring efficient stirring.

35 In step (B), the first reaction product, i.e. P^A, is treated with an C₁-C₄ alkanol such as methanol, ethanol, *n*-propanol, *iso*-propanol, *n*-butanol, *iso*-butanol or *sec*-butanol. Particularly useful solvents are methanol, ethanol, *n*-propanol or *iso*-propanol. An especially useful alkanol is *iso*-propanol.

In step (B) the molar ratio of the C₁-C₄ alkanol to the compound of Formula 2 is in the range of 2.5:1.0 to 1.8:1.0. A particularly useful molar ratio of the C₁-C₄ alkanol to the compound of Formula 2 is 2.0:1.0.

Treatment of the first reaction product P^A in step (B) with a C₁-C₄ alkanol can be carried out under a broad range of temperatures, i.e. temperatures in the range of 20 to 80 °C. Temperatures in the range of 50 to 80 °C are particularly useful.

In step (C), the second reaction product, i.e. P^B, is treated with a protic acid in the presence of water. Examples of protic acids include, but are not limited to acetic acid, hydrochloric acid, citric acid, formic acid and sulfuric acid. A particularly useful acid is acetic acid.

In step (C) the molar ratio of the protic acid to the compound of Formula 2 is in the range of 3.0:1.0 to 2.0:1.0. A particularly useful molar ratio of the protic acid to the compound of Formula 2 is 2.5:1.0.

Treatment of the second reaction product P^B in step (C) with a protic acid can be carried out in the temperature range of 20 to 30 °C.

Reaction progress can be monitored by conventional methods such as HPLC and ¹H NMR analyses of aliquots.

The compounds of Formula 2 and Formula 3 used in step (A) of the invention are prepared as described in PCT Patent Publication WO 2010/129500. Many Aluminum reagents of Formula 4 are commercially available.

The compound of Formula 1 can optionally be isolated by standard techniques known in the art, including filtration, extraction, evaporation, and crystallization. As the compound of Formula 1 is a solid at ambient temperature, it is most easily isolated by filtration, optionally followed by washing with water and/or an organic solvent (xylenes, toluene, *n*-chlorobutane). Additional product can be isolated by concentrating the filtrate under reduced pressure, slurrying the resulting residue in an organic solvent, filtering and optionally washing with water and/or an organic solvent (xylenes, toluene, *n*-chlorobutane). The solid product can be further purified by recrystallization from an appropriate organic solvent.

The solid state of Compound 1 is preparable in more than one solid form. These solid forms include an amorphous solid form, in which there is no long-range order in the positions of molecules (e.g., foams and glasses). These solid forms also include crystalline forms, in which constituent molecules are arranged in an orderly repeating pattern extending in all three spatial dimensions. The term "polymorph" refers to a particular crystalline form of a chemical compound that can exist in more than one crystal structure (e.g. lattice type) in the solid state. Crystalline forms of Compound 1 in this invention relate to single polymorphs (i.e. single crystalline form). Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability,

melting point, hygroscopicity, suspensibility, solubility, dissolution rate and biological availability. One skilled in the art will appreciate that a polymorph of Compound **1** can exhibit beneficial effects (e.g., suitability for preparation of useful formulations, stability, improved biological performance) relative to another polymorph or a mixture of polymorphs of Compound **1**. Differences with respect to chemical stability, filterability, solubility, hygroscopicity, melting point, solid density and flowability can have a significant effect on the development of production methods and formulations, and efficacy of nematode control.

One crystalline polymorph form of Compound **1**, designated as polymorph Form TS, is a 1:1 (molar ratio) toluene solvate. Polymorph Form TS can be characterized by X-ray powder diffraction.

The powder X-ray diffraction pattern of polymorph Form TS of Compound **1** is shown in Figure 1. The corresponding 2θ values are tabulated in Table 1 of Characterization Example 1. Polymorph Form TS of Compound **1** can be identified by a room-temperature powder Cu(K α 1) X-ray diffraction pattern having at least the 2θ reflection positions (in degrees)

2θ	2θ
28.913	22.429
26.942	20.325
25.672	19.053
24.451	18.603
23.316	12.871

Polymorph Form TS can be prepared directly during the preparation of Compound **1** from its starting materials in the presence of toluene solvent as described in Preparation Example 1.

A second crystalline polymorph form of Compound **1** is designated as polymorph Form A. This solid form is unsolvated. Polymorph Form A can be characterized by its powder X-ray diffraction pattern.

The powder X-ray diffraction pattern of polymorph Form A of Compound **1** is shown in Figure 1. The corresponding 2θ values are tabulated in Table 2 of Characterization Example 2. Polymorph Form A of Compound **1** can be identified by a room-temperature powder Cu(K α 1) X-ray diffraction pattern having at least the 2θ reflection positions (in degrees)

2θ	2θ
30.367	25.973
29.131	25.604
27.995	24.285
27.611	23.582

2θ	2θ
26.49	19.789

Polymorph form A can be prepared from Polymorph Form TS as described in Preparation Example 2.

Polymorph Form A can also be prepared directly during the preparation of Compound 1 from its starting materials in the presence of *n*-chlorobutane solvent as described in Preparation Example 3.

A third crystalline polymorph form of Compound 1 designated as polymorph Form XS is a xylenes solvate. Polymorph Form XS can be characterized by its powder X-ray diffraction pattern.

The powder X-ray diffraction pattern of polymorph Form XS of Compound 1 is shown in Figure 1. The corresponding 2θ values are tabulated in Table 3 of Characterization Example 3. Polymorph Form XS of Compound 1 can be identified by a room-temperature powder Cu(K α 1) X-ray diffraction pattern having at least the 2θ reflection positions (in degrees)

2θ	2θ
30.767	24.836
28.964	24.100
28.045	23.499
26.324	22.397
25.621	19.906

Polymorph Form XS can be prepared directly during the preparation of Compound 1 from its starting materials in the presence of xylenes solvent as described in Preparation Example 4.

Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following Examples are, therefore, to be construed as merely illustrative, and not limiting of the disclosure in any way whatsoever. Abbreviations used in the examples are as follows: rpm is revolutions per minute, pXRD is powder X-ray diffraction, wt% is percent by weight measured by HPLC (using a calibration standard), a% is percent by area measured by HPLC at a wavelength of 230 nm.

Analytical methods used in the preparation examples are described below or in the Characterization Examples.

Powder X-Ray Diffraction (p-XRD)

Powder X-ray diffraction was used to identify the crystalline phases of various samples of Compound 1. Data were obtained with a Philips X'PERT automated powder diffractometer, Model 3040. The radiation produced by a copper anode X-ray source

includes Cu-K(alpha1), Cu-K(alpha2) and Cu-K(beta). The diffractometer was equipped with a nickel filter that removes the Cu-K(beta) radiation leaving Cu-K(alpha1) and Cu-K(alpha2) in the raw data. The peaks originating from Cu-K(alpha 2) are removed during the find peaks routine in the Jade Software (MDI/Jade software version 9.1) leaving the listed maxima from Cu-K(alpha1). The wavelength for Cu-K(alpha1) or Cu(K α 1) radiation listed in International Tables for X-ray Crystallography is 0.154056 nm.

High Performance Liquid Chromatography (HPLC)

HPLC analyses were performed using a Hewlett Packard 1100 series HPLC system with DAD/UV detector and reverse-phase column (Agilent Eclipse XDB-C8 (4.6 x 150) mm, 5 μ m, Part. No. 993967-906). Flow rate was 1.0 mL/min, run time 25 min, injection volume 3.0 μ L, and the column temperature was 40 °C. Mobile phase A was 0.075% orthophosphoric acid (aq) and mobile phase B was acetonitrile (HPLC grade). For wt% determination the concentration of the test sample was calibrated against a standard sample, and a% purity reported from the sample chromatogram. Peaks appearing in the blank sample were not integrated, all other peaks were integrated and a% purity reported from the sample chromatogram. For wt% determination the concentration of test sample was calibrated against the standard sample.

Proton – Nuclear Magnetic Resonance (^1H NMR)

Proton-NMR analysis was performed on a Bruker Advance 300/400 instrument. The operational frequency was 400 MHz, spectral frequency range 0-16 ppm, delay time 2 seconds, pulse width of 12 μ s, minimum number of scans was 8. Samples were prepared by weighing about 0.01 g of samples or reference standards, adding 0.6 mL of DMSO- d_6 to dissolve the contents and transferring into NMR tubes. Deuterated DMSO (DMSO- d_6) was from Cambridge Isotope Laboratory. ^1H NMR spectra are reported in ppm downfield from tetramethylsilane; “s” means singlet, “d” means doublet and “dd” means doublet of doublets.

PREPARATION EXAMPLE 1

Preparation of Toluene Solvate Form of 8-chloro-*N*-[(2-chloro-5-methoxyphenyl)sulfonyl]-6-(trifluoromethyl)-imidazo[1,2-*a*]pyridine-2-carboxamide (Form TS)

A stirred slurry of 8-chloro-6-(trifluoromethyl)imidazo[1,2,*a*]pyridine-2-carboxylic acid ethyl ester (see PCT Patent Publication WO 2010/129500 for preparation) (10 g, 33.7 mmol based on HPLC wt% = 98.9 %) and 2-chloro-5-methoxybenzenesulfonamide (see PCT Patent Publication WO 2010/129500 for preparation) (8 g, 35.9 mmol, 1.05 equiv) in toluene (70 mL) at 23 °C under nitrogen was heated to 55 °C over a period of 60 min. To this slurry under nitrogen was added 1M diethyl aluminum chloride in toluene (34 mL, 33.7 mmol, 1 equiv) over approximately 10 minutes. The addition of diethylaluminum chloride was accompanied by ca. 10 °C temperature rise and moderate foaming. After complete addition of diethylaluminum chloride the temperature of the reaction mixture was adjusted to

75 °C over a period of 30 min. The reaction mixture was held with efficient stirring for 4 h at 73-75 °C during which it became a very thick slurry. After about 4 h, HPLC analysis indicated <1 area % of 8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester remaining. *Iso*-propanol (5.2 mL, 68.3 mmol, 2 equiv) was added and the mixture was subsequently cooled to 20-25 °C. Aqueous 10% acetic acid (47 mL, 85.4 mmol, 2.5 equiv) was then added over a period of 1 h at 20-35 °C. The reaction was held for an additional 1 h at 25 °C and then filtered, washed successively with water (80 mL) and toluene (20 mL), and suction-dried for 5 h. The solid product was further dried in a vacuum oven at 80 °C for 90 h to give the title compound (13.7 g) as an off-white solid with purity = 98.6 a% (by HPLC); assay = 97.9 wt% (by HPLC).

¹H-NMR was consistent with Compound 1 [(DMSO-d₆) δ 3.86 (s, 3H), 7.30 (d, 1H), 7.57 (dd, 1H), 7.64 (d, 1H), 7.96 (d, 1H), 8.84 (s, 1H), 9.34 (d, 1H)] containing toluene. The molar ratio of toluene and Compound 1 is 1 indicating a 1:1 toluene solvate. The polymorph Form TS was characterized by its powder X-ray diffraction pattern (See Characterization Example 1).

PREPARATION EXAMPLE 2

Conversion of the Toluene Solvate Form of Compound 1 to Form A

To a 500 mL three-neck round-bottom flask equipped with overhead stirrer, oil bath, a Dean-Stark apparatus and temperature probe was charged 25 g of Compound 1 (toluene content = 17.3 wt%) and water (75 mL) at 25 °C. The resultant reaction mass was heated to 95 °C (reaction mass temperature) and maintained at 95-96 °C over a period of 5 h while stirring at about 850 rpm. The water collected from the Dean-Stark apparatus was recycled to maintain about constant reaction volume while toluene was removed from the reaction mixture. After about 3 h no further distillation of toluene was observed. A slurry sample was taken from the reaction mass under agitation. The toluene and ethyl acetate content of the slurry was determined by GC analysis as 56 ppm and 17 ppm, respectively. About 10 mL of the sample was taken from the reaction mixture, cooled to 25 °C, filtered and vacuum dried on a Büchner funnel for 15 min. The wet cake showed about 429 ppm of toluene and 36 ppm of ethyl acetate. The wet cake was dried in a vacuum oven at 55 °C (8-15 kPa absolute pressure) for about 1 hour to afford the title compound.

¹H-NMR was consistent with Compound 1 [(DMSO-d₆) δ 3.86 (s, 3H), 7.30 (d, 1H), 7.57 (dd, 1H), 7.64 (d, 1H), 7.96 (d, 1H), 8.84 (s, 1H), 9.34 (d, 1H)] in unsolvated form. Polymorph Form A was characterized by its powder X-ray diffraction pattern (See Characterization Example 2).

Since the portion of the sample from the reaction mass indicated the conversion to Form A, the entire reaction mass was filtered, dried in a vacuum oven (8-15 kPa absolute pressure) at 55 °C for 1 h to afford additional title compound.

PREPARATION EXAMPLE 3

Direct Preparation of Polymorph Form A of 8-chloro-*N*-[(2-chloro-5-methoxyphenyl)sulfonyl]-6-(trifluoromethyl)-imidazo[1,2-*a*]pyridine-2-carboxamide

A stirred slurry of 8-chloro-6-(trifluoromethyl)imidazo[1,2,*a*]pyridine-2-carboxylic acid ethyl ester (3.0 g, 10.3 mmol) and 2-chloro-5-methoxybenzenesulfonamide (2.39 g, 10.8 mmol, 1.05 equiv) in *n*-chlorobutane (45 mL) was heated to 50 °C under nitrogen. To this slurry was added neat diethylaluminum chloride (1.40 mL, 11.3 mmol). After complete addition of diethylaluminum chloride the temperature of the reaction mixture was adjusted to 65-70 °C and was held at this temperature for 4.5 h. An additional portion of *n*-chlorobutane (12 mL) was added and heating at 70 °C was continued for an additional 1.5 h. *Iso*-propanol (1.6 mL, 20.5 mmol, 2 equiv) was added at 70 °C and the resulting mixture stirred for 5 min. Aqueous 10% acetic acid (15 mL, 25.6 mmol, 2.5 equiv) was then added over a period of 10 min at 60-65 °C. The reaction was allowed to cool to room temperature and then stirred overnight. The resulting solid was filtered, washed with water (12 mL) followed by *n*-chlorobutane (12 mL), and suction-dried. The solid product was further dried in a vacuum oven at 50-60 °C to give the title compound (4.09 g, 85.2%). Powder X-ray diffraction data conformed with Form A of Compound 1 as in Characterization Example 2.

PREPARATION EXAMPLE 4

Preparation of Xylene Solvate Form of 8-chloro-*N*-[(2-chloro-5-methoxyphenyl)sulfonyl]-6-(trifluoromethyl)-imidazo[1,2-*a*]pyridine-2-carboxamide (Form XS)

A stirred slurry of 8-chloro-6-(trifluoromethyl)imidazo[1,2,*a*]pyridine-2-carboxylic acid ethyl ester (5.0 g, 17.1 mmol) and 2-chloro-5-methoxybenzenesulfonamide (3.98 g, 17.9 mmol) in xylenes (60 mL) at 23 °C under nitrogen was heated to 60 °C. To this slurry was added neat diethyl aluminum chloride (2.4 mL, 18.8 mmol) over approximately 5 minutes. The addition of diethylaluminum chloride was accompanied by ca. 15 °C temperature rise and moderate foaming. Heating was continued for 1.5 h. The reaction mixture was then diluted with xylenes (5 mL) and then heated at 60 °C for an additional 2 h. The reaction mixture was cooled to 53 °C. *Iso*-propanol (2.6 mL, 34.17 mmol) was added and the reaction mixture subsequently cooled to 20-25 °C. Hydrochloric acid (2N, 22 mL, 42.7 mmol) was then added over a period of 30 min. The reaction was then filtered, washed successively with water (20 mL) and xylenes (10 mL) to yield a solid. A portion of the solid product (1.5 g) was slurried in a mixture of acetic acid (0.75 mL) and water (15 mL), heated to 75 °C with efficient stirring, and held at this temperature for 4 h. The reaction mixture was filtered hot and the filtered solid washed with water (6 mL) and the solid dried in a vacuum oven at 45 °C overnight to give the title compound (0.91 g) as an off-white solid.

¹H-NMR was consistent with Compound 1 [(DMSO-*d*₆) δ 3.86 (s, 3H), 7.30 (d, 1H), 7.57 (dd, 1H), 7.64 (d, 1H), 7.96 (d, 1H), 8.84 (s, 1H), 9.34 (d, 1H)] containing xylenes. The

polymorph Form XS was characterized by its powder X-ray diffraction pattern (See Characterization Example 3).

PREPARATION EXAMPLE 5

Direct Preparation of Polymorph Form A of 8-chloro-*N*-[(2-chloro-5-methoxyphenyl)-sulfonyl]-6-(trifluoromethyl)-imidazo[1,2-*a*]pyridine-2-carboxamide

To a stirred slurry of 8-chloro-6-(trifluoromethyl)imidazo[1,2,*a*]pyridine-2-carboxylic acid ethyl ester (see PCT Patent Publication WO 2010/129500 for preparation) (8 g, 27.3 mmol) and 2-chloro-5-methoxybenzenesulfonamide (see PCT Patent Publication WO 2010/129500 for preparation) (6.4 g, 28.7 mmol, 1.05 equiv) in 1,2-dichloroethane (41 mL) at 22 °C under nitrogen was added diethylaluminum chloride (4 mL, 31.9 mmol, 1.18 equiv) over approximately 5 minutes. The addition of diethylaluminum chloride was accompanied by about 23 °C temperature rise and moderate foaming. After complete addition of diethylaluminum chloride the temperature of the reaction mixture was adjusted to 75 °C. The reaction mixture was held with efficient stirring for about 1.5 h at 75 °C during which it became an off-white slurry. After about 1.5 h, HPLC analysis indicated <1 area % of 8-chloro-6-(trifluoromethyl)imidazo[1,2,*a*]pyridine-2-carboxylic acid ethyl ester remaining. Aqueous 10% acetic acid (41 mL, 68.3 mmol, 2.5 equiv) was then added resulting in some frothing and the reaction mass transformed to a thick slurry and then to a clear biphasic solution. The reaction mass was then cooled down to 45 °C and the two phases separated. The organic phase was then transferred to a jacketed-reactor together with additional 1,2-dichloroethane (20 mL) that was used to dissolve some precipitated solids. The organic phase was heated to distill 1,2-dichloroethane under atmospheric pressure. After collection of about 30 ml of the distillate, acetic acid (17 mL) was added to the jacketed-reactor and distillation continued. When the reactor's temperature reached 102 °C, water (64 mL) was added to it and distillation continued. After collection of another 30 mL of distillate, water (about 40 mL) was added to the reactor, the distillation was ended and the batch brought down to room temperature. The batch was then warmed to 75 °C and held stirring for about 5.5h. The batch was then cooled to room temperature and then filtered. The filter cake was washed with water (20 ml). The solid product was split into two portions, the larger portion was dried in a vacuum oven at 80 °C for 16 hours and the smaller portion was air-dried for 16 hours to give the title compound (9.98 g and 1.48g respectively) in 89.6% combined yield and with purity = 96.7 a% (by HPLC). Both the air-dried and the vacuum-dried product conformed with polymorph Form A. The polymorph Form A was characterized by its powder X-ray diffraction pattern (See Characterization Example 2).

PREPARATION EXAMPLE 6

Direct Preparation of Polymorph Form A of 8-chloro-*N*-[(2-chloro-5-methoxyphenyl)-sulfonyl]-6-(trifluoromethyl)-imidazo[1,2-*a*]pyridine-2-carboxamide

To a stirred slurry of 8-chloro-6-(trifluoromethyl)imidazo[1,2,*a*]pyridine-2-carboxylic acid ethyl ester (see PCT Patent Publication WO 2010/129500 for preparation) (3 g, 10.3 mmol) and 2-chloro-5-methoxybenzenesulfonamide (see PCT Patent Publication WO 2010/129500 for preparation) (2.4 g, 10.8 mmol, 1.05 equiv) in dichloromethane (24 mL) at 17 °C under nitrogen was added diethyl aluminum chloride (1.5 mL, 12.0 mmol, 1.16 equiv) over approximately 1 minute. The addition of diethylaluminum chloride was accompanied by ca. 13 °C temperature rise and gas evolution. After complete addition of diethylaluminum chloride the temperature of the reaction mixture was adjusted to 40 °C and the batch became an off-white slurry. The reaction mixture was held stirring for about 24 h at 40 °C. HPLC analysis (after 24 h) indicated 3.6 area % of 8-chloro-6-(trifluoromethyl)imidazo[1,2,*a*]pyridine-2-carboxylic acid ethyl ester remaining. *Iso*-propyl alcohol (1.6 mL) and heptane (12 mL) were respectively added to the reaction resulting in formation of a thicker slurry. Aqueous 10% acetic acid (15 mL, 25.6 mmol, 2.5 equiv) was then added resulting in a strong exotherm. The reaction mass was held for about 1.5 h at 20-25 °C and was then filtered and the filter cake was washed with water (12 mL). The solid product was split into two portions, the larger portion was dried in a vacuum oven at 80 °C for 16 hours and the smaller portion was air-dried for 16 hours to give the title compound (2.8 g and 0.95g respectively) in 86.8% combined yield. The vacuum-dried product conformed with polymorph Form A and the air-dried portion did not. The polymorph Form A was characterized by its powder X-ray diffraction pattern (See Characterization Example 2).

CHARACTERIZATION EXAMPLE 1

X-Ray Powder Diffraction Pattern for Compound 1 Polymorph Form TS (BA9507)

Powder X-ray diffraction was used to characterize the toluene solvate polymorph form (Polymorph Form TS) of Compound 1. Data were obtained with a Philips X'PERT automated powder diffractometer, Model 3040. The diffractometer was equipped with automatic variable anti-scatter and divergence slits, X'Celerator RTMS detector, and Ni filter. The radiation was Cu-K(alpha) (45 kV, 40 mA). Data were collected at room temperature from 3 to 50 degrees 2-theta using a continuous scan with an equivalent step size of 0.02 degrees and a count time of 320 seconds per step in theta-theta geometry. Samples were lightly ground with an agate mortar and pestle as needed and prepared on low background silicon specimen holders as a thin layer of powdered material. MDI/Jade software version 9.1 was used with the International Committee for Diffraction Data

database PDF4+ 2008 for phase identification. Cu-K(alpha1) X-ray diffraction maxima for Form TS of Compound 1 were calculated using the MDI/Jade “Find Peaks” routine and are listed Table 1.

Table 1

2θ X-ray Maxima (in degrees) for Polymorph Form TS of Compound 1

<u>2θ</u>	<u>2θ</u>	<u>2θ</u>	<u>2θ</u>	<u>2θ</u>	<u>2θ</u>	<u>2θ</u>
6.889	14.508	18.603	24.451	32.222	36.906	42.015
8.608	14.908	19.053	25.672	32.671	37.452	43.869
9.997	15.728	20.325	26.942	33.561	38.323	45.173
11.433	16.481	21.643	27.945	33.994	39.057	46.092
12.871	16.998	22.429	28.913	34.528	40.711	47.514
13.606	17.433	23.316	30.951	36.114	41.548	48.148

CHARACTERIZATION EXAMPLE 2

X-Ray Powder Diffraction for Compound 1 Polymorph Form A

Powder X-ray diffraction was used to identify the crystalline phases of various samples of Compound 1. Data were obtained with a Philips X'PERT automated powder diffractometer, Model 3040. The diffractometer was equipped with automatic variable anti-scatter and divergence slits, X'Celerator RTMS detector, and Ni filter. The radiation was Cu-K(alpha) (45 kV, 40 mA). Data were collected at room temperature from 3 to 50 degrees 2-theta using a continuous scan with an equivalent step size of 0.02 degrees and a count time of 320 seconds per step in theta-theta geometry. Samples were ground with an agate mortar and pestle as needed and prepared on low background amorphous silica specimen holders as a thin layer of powdered material. MDI/Jade software version 9.1 is used with the International Committee for Diffraction Data database PDF4+ 2008 for phase identification. Cu-K(alpha1) X-ray diffraction maxima for Form A of Compound 1 were calculated using the MDI/Jade “Find Peaks” routine and are listed Table 2.

Table 2

2θ X-ray Maxima (in degrees) for Polymorph Form A of Compound 1

<u>2θ</u>	<u>2θ</u>	<u>2θ</u>	<u>2θ</u>	<u>2θ</u>	<u>2θ</u>	<u>2θ</u>
11.651	21.026	25.973	30.652	36.967	42.451	47.813
12.854	21.543	26.490	31.905	37.703	42.935	48.167
13.705	23.097	27.308	32.657	37.956	43.538	48.648
14.056	23.582	27.611	33.042	38.607	44.089	49.118
15.426	24.285	27.995	34.629	38.992	44.740	49.502
18.286	24.584	29.131	35.028	39.875	45.926	
18.836	24.954	29.764	35.614	40.443	46.644	
19.789	25.604	30.367	35.982	41.632	47.279	

CHARACTERIZATION EXAMPLE 3

X-Ray Powder Diffraction for Compound 1 Polymorph Form XS

Powder X-ray diffraction was used to characterize the xylene solvate polymorph form (Polymorph Form XS) of Compound 1. Data were obtained with a Philips X'PERT automated powder diffractometer, Model 3040. The diffractometer was equipped with automatic variable anti-scatter and divergence slits, X'Celerator RTMS detector, and Ni filter. The radiation was Cu-K(alpha) (45 kV, 40 mA). Data were collected at room temperature from 3 to 50 degrees 2-theta using a continuous scan with an equivalent step size of 0.02 degrees and a count time of 320 seconds per step in theta-theta geometry. Samples were lightly ground with an agate mortar and pestle as needed and prepared on low background silicon specimen holders as a thin layer of powdered material. MDI/Jade software version 9.1 was used with the International Committee for Diffraction Data database PDF4+ 2008 for phase identification. Cu-K(alpha) X-ray diffraction maxima for Form XS of Compound 1 were calculated using the MDI/Jade "Find Peaks" routine and are listed Table 1.

Table 3


2θ X-ray Maxima (in degrees) for Polymorph Form XS of Compound 1

<u>2θ</u>	<u>2θ</u>	<u>2θ</u>	<u>2θ</u>	<u>2θ</u>	<u>2θ</u>	<u>2θ</u>
6.786	13.273	19.306	24.1	28.964	35.293	39.853
8.392	14.593	19.906	24.836	29.365	35.816	40.536
9.911	16.394	20.707	25.621	30.767	37.164	41.402
11.283	17.233	21.045	26.324	31.415	37.472	44.356
12.45	17.934	22.397	27.359	33.355	38.521	44.906
12.903	18.719	23.499	28.045	33.876	38.909	47.58


CLAIMS

What is claimed is:

1. A method for preparing a compound of Formula 1




- 5 comprising (A) contacting a compound of Formula 2




wherein

R¹ is C₁-C₄ alkyl

with a compound of Formula 3



and at least one aluminum reagent of Formula 4



- 10 wherein

R²ᵃ, R²ᵇ and R²ᶜ are each independently H, Cl or C₁-C₄ alkyl
in the presence of an inert solvent to form a first reaction product,

(B) contacting the first reaction product with an C₁-C₄ alkanol to form a second reaction product

and (C) contacting the second reaction product with water and a protic acid to give the compound of Formula 1.

- 5 2. The method of Claim 1 wherein R¹ is CH₃ or CH₂CH₃.
3. The method of Claim 1 wherein the at least one aluminum reagent of Formula 4 comprises one or more compounds selected from the group consisting of ClAl(CH₂CH₃)₂, Cl₂Al(CH₂CH₃), Al(CH₂CH₃)₃, Al(CH₃)₃, Al[CH₂CH(CH₃)₂]₃ and HAl[CH₂CH(CH₃)₂]₂.
4. The method of Claim 3 wherein the at least one aluminum reagent of Formula 4
10 comprises ClAl(CH₂CH₃)₂.
5. The method of Claim 1 wherein the inert solvent comprises one or more solvents selected from the group consisting of C₁-C₆ haloalkanes, halogenated benzenes and C₇-C₁₀ aromatic hydrocarbons.
6. The method of Claim 5 wherein the inert solvent comprises one or more solvents
15 selected from the group consisting of toluene, xylenes, ethylbenzene, cumene, 1,2-dichloroethane, dichloromethane, 1,1,1-trichloroethane, chlorobenzene, 1,2-dichlorobenzene and *n*-chlorobutane.
7. The method of Claim 6 wherein the inert solvent comprises toluene.
8. The method of Claim 6 wherein the inert solvent comprises one or more solvents
20 selected from the group consisting of 1,2-dichloroethane, dichloromethane and *n*-chlorobutane.
9. The method of Claim 1 wherein in step (A) the temperature is in the range of 20 to 150 °C.
10. The method of Claim 1 wherein in step (A), the compound of Formula 2 and the
25 compound of Formula 3 are combined in the presence of an inert solvent and then the aluminum reagent of Formula 4 is added.
11. The method of Claim 1 wherein in step (B) the C₁-C₄ alkanol comprises one or more alkanols selected from the group consisting of methanol, ethanol, *n*-propanol, *iso*-propanol, *n*-butanol, *iso*-butanol and *sec*-butanol.
- 30 12. The method of Claim 11 wherein in step (B) the C₁-C₄ alkanol comprises *iso*-propanol.

13. The method of Claim 1 wherein in step (B) the temperature is in the range of 20 to 80 °C.

14. The method of Claim 1 wherein in step (C) the protic acid comprises one or more protic acids selected from the group consisting of acetic acid, hydrochloric acid, citric acid, formic acid and sulfuric acid.

15. The method of Claim 14 wherein in step (C) the protic acid comprises acetic acid.




FIG. 1

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2013/078398

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D471/04
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2010/129500 A2 (DU PONT [US]; LAHM GEORGE P [US]; LETT RENEE MARIE [US]; SMITH BRENTON) 11 November 2010 (2010-11-11) cited in the application step D on page 57	1-15
Y	US 4 511 392 A (RORER MORRIS P [US]) 16 April 1985 (1985-04-16) equation 1;; examples 14, 20, 25, 27 ----- -/--	1-15



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

13 February 2014

Date of mailing of the international search report

04/03/2014

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Sáez Díaz, R

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2013/078398

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DANIEL R. SIDLER ET AL: "Aluminum-Amine Complexes for the Conversion of Carboxylic Esters to Amides. Application to the Synthesis of LTD4 Antagonist MK-0679", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 59, no. 6, 1 March 1994 (1994-03-01), pages 1231-1233, XP055101473, ISSN: 0022-3263, DOI: 10.1021/jo00085a001 page 1232 - page 1233</p> <p>-----</p>	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2013/078398

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2010129500	A2	11-11-2010	AR 076838 A1 13-07-2011
		AU 2010246105 A1 06-10-2011	
		CA 2757075 A1 11-11-2010	
		CN 102413693 A 11-04-2012	
		CO 6450621 A2 31-05-2012	
		EP 2427058 A2 14-03-2012	
		JP 2012526125 A 25-10-2012	
		KR 20120034635 A 12-04-2012	
		MA 33261 B1 02-05-2012	
		NZ 595152 A 26-04-2013	
		TW 201040183 A 16-11-2010	
		US 2012114624 A1 10-05-2012	
		UY 32606 A 31-12-2010	
		WO 2010129500 A2 11-11-2010	

US 4511392	A	16-04-1985	CA 1239929 A1 02-08-1988
		US 4511392 A 16-04-1985	
